Drugs / NNC0090-2746
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02205528 | Aug 2014 → Sep 2015 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NNC0090-2746 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02205528 ↗ |
| Known as | RG7697 | “Here, we extend the characterization of NNC0090-2746 (also known as RG7697), a fatty-acylated dual agonist possessing in vitro balanced GIPR and GLP-1R agonism.” PMID 28768173 ↗ Aug 2017 |
| Action | Activate | “balanced GIPR and GLP-1R agonism” PMID 28768173 ↗ Aug 2017 |
| Modality | Peptide | “Unimolecular dual incretins derived from hybridized glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) sequences” PMID 28768173 ↗ Aug 2017 |
| Route | Subcutaneous | “via SC injection” NCT02205528 ↗ |
| Target | GIPR | “possessing in vitro balanced GIPR and GLP-1R agonism” PMID 28768173 ↗ Aug 2017 |